![Michael Pehl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Pehl
Director Ejecutivo en
ADCendo ApS
.
Perfil
Michael Pehl is Chief Executive Officer & Director at ADCendo ApS since 2021.
Formerly, Mr. Pehl was President, Chief Executive Officer & Director at Immunomedics, Inc. from 2017 to 2019, Chief Executive Officer at AvenCell Europe GmbH, and President-Global Hematology/Oncology at Celgene Corp.
from 2006 to 2017.
Mr. Pehl completed undergraduate education at Ludwig-Maximilians-Universität München.
Cargos activos de Michael Pehl
| Empresas | Cargo | Inicio |
|---|---|---|
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Director Ejecutivo | 07/07/2021 |
Antiguos cargos conocidos de Michael Pehl.
| Empresas | Cargo | Fin |
|---|---|---|
| IMMUNOMEDICS, INC. | Director Ejecutivo | 23/02/2019 |
| CELGENE | Corporate Officer/Principal | 21/08/2017 |
GEMoaB Monoclonals GmbH
 GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Director Ejecutivo | - |
Formación de Michael Pehl.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
77
Relaciones de 1er grado
5
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Health Technology |
GEMoaB Monoclonals GmbH
GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
- Bolsa de valores
- Insiders
- Michael Pehl
